Relapse following chimeric antigen receptor (CAR) T-cell therapy directed against CD19 for
relapsed/refractory B-acute lymphoblastic leukemia (r/r B-ALL) remains a significant …

The event-free survival (EFS) for pediatric acute lymphoblastic leukemia (ALL) has shown
remarkable improvement in the past several decades. In Korea also, a recent study showed …

The prognosis for infants with acute lymphoblastic leukemia (ALL), particularly those with
KMT2A gene rearrangement (KMT2A-r), is dismal. Continuous efforts have been made in …

Abstract Purpose of the Review Infant leukemia is a rare, distinct subgroup of pediatric acute
leukemias diagnosed in children under 1 year of age and characterized by unique …

KMT2A-rearranged infant acute lymphoblastic leukemia (ALL) represents the most refractory
type of childhood leukemia. To uncover the molecular heterogeneity of this disease, we …

Outcomes for infants diagnosed under 1 year of age with KMT2A-rearranged acute
lymphoblastic leukemia (ALL) have remained stagnant over the past 20 years. Successive …

The survival rate of children with acute lymphoblastic leukemia (ALL) has increased to
approximately 90% after substantial progress in risk-oriented treatment strategies. Between …

Infants with B-cell acute lymphoblastic leukemia (B-ALL) continue to have significantly worse
outcomes compared to older children with B-ALL, and those with relapsed or refractory (R/R) …

Acute lymphoblastic leukemia (ALL) in infants (o1 year of age) is an aggressive disease.
About 80% of infant ALL patients harbor a mixed lineage leukemia (MLL) translocation …

The role of allogeneic hematopoietic stem cell transplantation (HSCT) for infants with acute
lymphoblastic leukemia (ALL) and KMT2A gene rearrangement (KMT2A-r) is controversial in …